Bivalirudin (TFA)

Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others[1][2][3][4].

Product Specifications

CAS Number

[1191386-55-6]

UNSPSC

12352209

Target

Interleukin Related; RSV; Thrombin

Type

Peptides

Related Pathways

Anti-infection; Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Infection; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Bivalirudin-Trifluoroacetate.html

Purity

99.89

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 50 mg/mL

Smiles

C(C(O)=O)(F)(F)F.C([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC1=CC=CC=C1)NC([C@@H](NC(CNC([C@@H](NC(CNC(CNC(CNC(CNC(=O)[C@H]2N(C([C@@H](NC(=O)[C@H]3N(C([C@@H](CC4=CC=CC=C4)N)=O)CCC3)CCCNC(=N)N)=O)CCC2)=O)=O)=O)=O)CC(N)=O)=O)=O)CC(O)=O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)[C@H](CC)C)(=O)N5[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC6=CC=C(O)C=C6)C(N[C@@H](CC(C)C)C(O)=O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCC5

Molecular Formula

C98H138N24O33.C2HF3O2

Molecular Weight

2294.34

References & Citations

[1]Ye H, et al. Bivalirudin Attenuates Thrombin-Induced Endothelial Hyperpermeability via S1P/S1PR2 Category: Original Articles. Front Pharmacol. 2021 Aug 3;12:721200.|[2]Zhuang S, et al. Bivalirudin exerts antiviral activity against respiratory syncytial virus-induced lung infections in neonatal mice. Acta Pharm. 2022 Apr 13;72 (3) :415-425.|[3]Warkentin TE, et al. Bivalirudin: a review. Expert Opin Pharmacother. 2005 Jul;6 (8) :1349-71.|[4]André P, et al. Anticoagulants (thrombin inhibitors) and aspirin synergize with P2Y12 receptor antagonism in thrombosis.Circulation. 2003 Nov 25;108 (21) :2697-703.